A Phase II Study Evaluating the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Untreated Follicular Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05410418

Title field or adapter rule

{'original_value': 'A Phase II Study Evaluating the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Untreated Follicular Lymphoma', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-11-01T01:03:15.784758+00:00

Published At

2026-10-28T00:00:00+00:00

Record Updated At

2026-10-28

Results Posted At

2026-10-28

Source Retrieved At

2026-11-01T01:03:15.424322+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Lymphoma, Follicular", "Follicular Lymphoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT05410418"

protocolSection.identificationModule.officialTitle

"A Phase II Study Evaluating the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Untreated Follicular Lymphoma"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

Study condition terms

• Lymphoma, Follicular (protocolSection.conditionsModule.conditions)
• Follicular Lymphoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Mosunetuzumab and Polatuzumab Vedotin'], 'description': 'Mosunetuzumab is administered subcutaneously using a "step-up" dosing strategy. The initial dose on C1D1 will be 5 mg, and doses thereafter will be 45 mg.', 'name': 'Mosunetuzumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Mosunetuzumab and Polatuzumab Vedotin'], 'description': 'Polatuzumab vedotin is administered intravenously over 90 minutes for the initial dose, and over 30 minutes thereafter.', 'name': 'Polatuzumab vedotin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Mosunetuzumab (protocolSection.armsInterventionsModule.interventions[].name)
• Polatuzumab vedotin (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.